Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
MXCT
SellHot AirMaxCyte, Inc. · Healthcare · United States · $126M · Avg Vol: $903K/d
COMPANY DESCRIPTION
MaxCyte, Inc. is a leading provider of cell-engineering platform technologies, specializing in high-performance electroporation systems for cell-based therapies and drug discovery. The company's proprietary Flow Electroporation technology is utilized by major biopharmaceutical companies to engineer cells with high efficiency and viability. MaxCyte's competitive moat is secured by its extensive portfolio of commercial licenses, which generate recurring instrument, disposable, and milestone-based royalty revenues.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 44.3M | 41.3M | 38.6M | 33.0M | -9.3% | 31.1M | 31.4M | 37.2M | 6.1% |
| EPS | -0.23 | -0.37 | -0.39 | -0.42 | — | -0.34 | -0.28 | -0.25 | — |
| Shares | 102.4M | 104.0M | 105.7M | 106.8M | +4.3% | 103.2M | — | — | — |
| Debt | 16.1M | 18.7M | 18.0M | 17.9M | 3.7% | 17.3M | — | — | — |
| Equity | 254.0M | 232.2M | 206.3M | 171.5M | -12.3% | — | — | — | — |
| Op CF | -14.8M | -21.7M | -27.6M | -34.4M | — | -23.0M | — | — | — |
| Inv CF | -24.8M | 55.0M | 6.9M | 25.9M | — | — | — | — | — |
| Fin CF | 2.9M | 2.1M | 2.1M | 0.7M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of MXCT are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| MXCT | MaxCyte, Inc.(you) | $126M | 32 | Sell |
| LUNG | Pulmonx Corporation | $102M | 29 | Sell |
| ECOR | electroCore, Inc. | $87M | 32 | Sell |
| STIM | Neuronetics, Inc. | $224M | 33 | Sell |
| LNSR | LENSAR, Inc. | $102M | 22 | Sell |
| APYX | Apyx Medical Corporation | $130M | 18 | Strong Sell |
| MYO | Myomo, Inc. | $63M | 34 | Sell |
| INGN | Inogen, Inc. | $146M | 46 | Hold |
| QTRX | Quanterix Corporation | $125M | 14 | Strong Sell |
| OM | Outset Medical, Inc. | $74M | 24 | Sell |
Peer medians: ROE -30.8% · P/E 27.0x · Gross margin 58.1%